-
Alter G, Barouch D, 2018: Immune correlate-guided HIV vaccine design[J]. Cell Host Microbe, 24, 25-33. doi: 10.1016/j.chom.2018.06.012
-
Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude J-B, Lang J, 2012: Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses[J]. Virology, 429, 91-98. doi: 10.1016/j.virol.2012.03.007
-
Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, Borducchi EN, Smith KM, Nkolola JP, Liu J, 2015: Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys[J]. Science, 349, 320-324. doi: 10.1126/science.aab3886
-
Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, 2013: Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys[J]. Cell, 155, 531-539. doi: 10.1016/j.cell.2013.09.061
-
Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, 2000: A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure[J]. J Virol, 74, 627-643. doi: 10.1128/JVI.74.2.627-643.2000
-
Burton DR, Mascola JR, 2015: Antibody responses to envelope glycoproteins in HIV-1 infection[J]. Nat Immunol, 16, 571-576. doi: 10.1038/ni.3158
-
de Taeye SW, Moore JP, Sanders RW, 2016: HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies[J]. Trends Immunol, 37, 221-232. doi: 10.1016/j.it.2016.01.007
-
Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, 2009: Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies[J]. J Virol, 83, 188-199. doi: 10.1128/JVI.01583-08
-
Emmer KL, Wieczorek L, Tuyishime S, Molnar S, Polonis VR, Ertl HC, 2016: Antibody responses to prime-boost vaccination with an HIV-1 gp145 Env protein and chimpanzee adenovirus vectors expressing HIV-1 gp140[J]. AIDS (London, England), 30, 2405-. doi: 10.1097/QAD.0000000000001224
-
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp HIVVSG, 2005: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection[J]. J Infect Dis, 191, 654-665. doi: 10.1086/428404
-
Georgiev IS, Joyce MG, Yang Y, Sastry M, Zhang B, Baxa U, Chen RE, Druz A, Lees CR, Narpala S, 2015: Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env[J]. J Virol, 89, 5318-5329. doi: 10.1128/JVI.03451-14
-
He L, De Val N, Morris CD, Vora N, Thinnes TC, Kong L, Azadnia P, Sok D, Zhou B, Burton DR, 2016: Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles[J]. Nat Commun, 7, 1-15.
-
He L, Kumar S, Allen JD, Huang D, Lin X, Mann CJ, Saye-Francisco KL, Copps J, Sarkar A, Blizard GS, 2018: HIV-1 vaccine design through minimizing envelope metastability[J]. Science advances, 4, eaau6769-. doi: 10.1126/sciadv.aau6769
-
Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL, 2016: Achieving potent autologous neutralizing antibody responses against tier 2 HIV-1 viruses by strategic selection of envelope immunogens[J]. J Immunol, 196, 3064-3078. doi: 10.4049/jimmunol.1500527
-
Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, 2012: Broad and potent neutralization of HIV-1 by a gp41-specific human antibody[J]. Nature, 491, 406-412. doi: 10.1038/nature11544
-
Julien J-P, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse P-J, Burton DR, Sanders RW, Moore JP, 2013a: Crystal structure of a soluble cleaved HIV-1 envelope trimer[J]. Science, 342, 1477-1483. doi: 10.1126/science.1245625
-
Julien J-P, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, 2013b: Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9[J]. Proc Natl Acad Sci, 110, 4351-4356. doi: 10.1073/pnas.1217537110
-
Klasse P, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, 2016: Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 trimers from clades A, B and C[J]. PLoS Pathog, 12, e1005864-. doi: 10.1371/journal.ppat.1005864
-
Kong L, He L, De Val N, Vora N, Morris CD, Azadnia P, Sok D, Zhou B, Burton DR, Ward AB, 2016: Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability[J]. Nat Commun, 7, 1-15.
-
Lee JH, Ozorowski G, Ward AB, 2016: Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer[J]. Science, 351, 1043-1048. doi: 10.1126/science.aad2450
-
Lin Y, Böker A, He J, Sill K, Xiang H, Abetz C, Li X, Wang J, Emrick T, Long S, 2005: Self-directed self-assembly of nanoparticle/copolymer mixtures[J]. Nature, 434, 55-59. doi: 10.1038/nature03310
-
Liu L, Hao Y, Luo Z, Huang Y, Hu X, Liu Y, Shao Y, 2012: Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization[J]. Vaccine, 30, 4135-4143. doi: 10.1016/j.vaccine.2012.04.075
-
Montefiori DC, 2005: Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays[J]. Curr Protoc Immuno, 64, 12-11.
-
Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, 2011: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop[J]. J Virol, 85, 3128-3141. doi: 10.1128/JVI.02658-10
-
Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang G-Y, Ofek G, 2014: Structure and immune recognition of trimeric pre-fusion HIV-1 Env[J]. Nature, 514, 455-461. doi: 10.1038/nature13808
-
Pantaleo G, Koup RA, 2004: Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know[J]. Nat Med, 10, 806-810. doi: 10.1038/nm0804-806
-
Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, 2017: Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches[J]. Immunity, 46, 1073-1088. doi: 10.1016/j.immuni.2017.05.007
-
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Group BVE, 2006: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand[J]. J infect Dis, 194, 1661-1671. doi: 10.1086/508748
-
Sanders R, Van Gils M, Derking R, Sok D, Ketas T, Burger J, Ozorowski G, Cupo A, Simonich C, Goo L, 2015: HIV-1 vaccines. HIV-1 neutralizing antibodies induced by native-like envelope trimers[J]. Science, 349, aac4223-. doi: 10.1126/science.aac4223
-
Sanders RW, Derking R, Cupo A, Julien J-P, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, 2013: A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP 664. gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies[J]. PLoS pathog, 9, e1003618-. doi: 10.1371/journal.ppat.1003618
-
Sanders RW, Moore JP, 2017: Native-like Env trimers as a platform for HIV-1 vaccine design[J]. Immunol Rev, 275, 161-182. doi: 10.1111/imr.12481
-
Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, Moore JP, Binley JM, 2000: Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits[J]. J Virol, 74, 5091-5100. doi: 10.1128/JVI.74.11.5091-5100.2000
-
Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, 2002: Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1[J]. J Virol, 76, 8875-8889. doi: 10.1128/JVI.76.17.8875-8889.2002
-
Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, Housman M, Bouton-Verville H, Shen X, Trama AM, 2017: Vaccine induction of heterologous tier 2 HIV-1 neutralizing antibodies in animal models[J]. Cell Rep, 21, 3681-3690. doi: 10.1016/j.celrep.2017.12.028
-
Saunders KO, Wiehe K, Tian M, Acharya P, Bradley T, Alam SM, Go EP, Scearce R, Sutherland L, Henderson R, 2019: Targeted selection of HIV-specific antibody mutations by engineering B cell maturation[J]. Science, 366, eaay7199-. doi: 10.1126/science.aay7199
-
Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, 2009: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals[J]. Nature, 458, 636-640. doi: 10.1038/nature07930
-
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, 2011: Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding[J]. Science, 333, 1633-1637. doi: 10.1126/science.1207227
-
Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, Dubrovskaya V, Ward AB, Wyatt RT, 2015: Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design[J]. Cell Rep, 11, 539-550. doi: 10.1016/j.celrep.2015.03.047
-
Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, 2009: Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm[J]. J Virol, 83, 7337-7348. doi: 10.1128/JVI.00110-09
-
Sliepen K, Ozorowski G, Burger JA, van Montfort T, Stunnenberg M, LaBranche C, Montefiori DC, Moore JP, Ward AB, Sanders RW, 2015: Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity[J]. Retrovirology, 12, 1-5. doi: 10.1186/s12977-014-0129-1
-
Tian R-R, Zhang M-X, Zhang L-T, Zhang X-L, Zheng H-Y, Zhu L, Pang W, Zhang G-H, Zheng Y-T, 2015: High immune activation and abnormal expression of cytokines contribute to death of SHIV89.6-infected Chinese rhesus macaques[J]. Adv Virol, 160, 1953-1966. doi: 10.1007/s00705-015-2455-6
-
Tokatlian T, Read BJ, Jones CA, Kulp DW, Menis S, Chang JY, Steichen JM, Kumari S, Allen JD, Dane EL, 2019: Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers[J]. Science, 363, 649-654. doi: 10.1126/science.aat9120
-
Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, 2009: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target[J]. Science, 326, 285-289. doi: 10.1126/science.1178746
-
Wang W, Liu Z, Zhou X, Guo Z, Zhang J, Zhu P, Yao S, Zhu M, 2019: Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy[J]. Nanomed: Nanotechnol Biol Med, 16, 69-78. doi: 10.1016/j.nano.2018.11.009
-
Ward AB, Wilson IA, 2017: The HIV-1 envelope glycoprotein structure: nailing down a moving target[J]. Immunol Rev, 275, 21-32. doi: 10.1111/imr.12507
-
Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, 2010: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1[J]. Science, 329, 856-861. doi: 10.1126/science.1187659